Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21564451 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL24555863 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL14651160 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL1052491 | 0.92 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2930651 | 0.92 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2930654 | 0.92 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL18618383 | 0.91 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL10137655 | 0.87 | ALDH1A1 (0.47) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL19484302 | 0.87 | ALDH1A1 (0.47) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL12723118 | 0.87 | ALDH1A1 (0.47) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-107001339-B | Novel compounds | 特殊治疗有限公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | NR1H2 3483/4885USP2 16/4885SMN1; SMN2 4629/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | NR1H2 2235/4885USP2 17/4885SMN1; SMN2 3529/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | NR1H2 3483/4885USP2 16/4885SMN1; SMN2 4629/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | NR1H2 3483/4885USP2 16/4885SMN1; SMN2 4629/4885 |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | NR1H2 3483/4885USP2 16/4885SMN1; SMN2 4629/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | NR1H2 2191/4885USP2 14/4885SMN1; SMN2 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.